This webinar describes one institution’s approach to broad molecular profiling of tumor samples using Next-Generation Sequencing (NGS).

The promise of precision oncology can only be realized when the genetic basis of each tumor sample is fully understood. However, the list of genes that can contribute to tumor progression and, subsequently, inform the therapeutic course of action for a given patient, continues to grow. Furthermore, the function of any gene can be altered by several types of variations, including single nucleotide variants, multiple nucleotide variants, small insertions or deletions, copy number variants, splice variations, and gene fusions. Therefore, it is difficult for researchers to analyze tumors efficiently when available methods only cover a portion of these variations, and sequential analysis consumes valuable tissue, time, and resources. Only when these barriers can be overcome can the application of NGS in clinical cancer research be fully evaluated.

In this webinar, Devin Absher from the Hudson Alpha Institute for Biotechnology discusses how his team is leveraging NGS assays to evaluate the potential of NGS in precision oncology. Dr. Absher discusses his team's approach to cancer research and offer case studies showing results of recent studies.